How is malignant hydatidiform mole treated with chemotherapy?
Nov 29, 2024
Source: Cainiu Health
Dr. Yang Ziqi
Introduction
In general, malignant hydatidiform mole refers to invasive hydatidiform mole. Invasive hydatidiform mole is a malignant trophoblastic tumor that develops following a molar pregnancy, characterized by varying degrees of invasion of molar tissue into the uterine muscle layer or other sites. Chemotherapy for invasive hydatidiform mole mainly includes two approaches: single-agent chemotherapy and combination chemotherapy. If discomfort symptoms occur, it is recommended to seek timely medical attention at a hospital.
In general, malignant hydatidiform mole refers to invasive hydatidiform mole. Invasive hydatidiform mole is a malignant trophoblastic tumor that develops following a molar pregnancy, characterized by the invasion of molar tissue into the uterine muscle layer or other sites to varying degrees. Chemotherapy for invasive hydatidiform mole mainly includes single-agent chemotherapy and combination chemotherapy. If discomfort symptoms occur, it is recommended to seek timely medical consultation at a hospital and follow standardized treatment under the guidance of a physician. Detailed analysis is as follows:
Commonly used chemotherapeutic drugs for invasive hydatidiform mole include methotrexate for injection, dactinomycin for injection, fluorouracil injection, ifosfamide for injection, vincristine sulfate for injection, and etoposide injection. If the condition of invasive hydatidiform mole is mild and categorized as low-risk, a single-agent chemotherapy regimen may be the first choice. During chemotherapy, only one chemotherapeutic agent is used. Commonly used single-agent chemotherapeutic drugs include methotrexate for injection, dactinomycin for injection, and fluorouracil injection. Methotrexate for injection is a folic acid reductase inhibitor that can inhibit DNA synthesis in tumor cells, thereby killing or inhibiting tumor cell growth; Dactinomycin for injection binds to DNA and inhibits RNA synthesis, thereby suppressing tumor cell growth; Fluorouracil injection is a thymidylate synthase inhibitor that can block DNA synthesis and exert cytotoxic effects on tumor cells.
If the condition of invasive hydatidiform mole is severe and categorized as high-risk, combination chemotherapy is usually selected when the patient's general condition is good and they can tolerate the side effects of combination chemotherapy. Combination chemotherapy helps improve chemosensitivity and enhance therapeutic effectiveness. For example, EMA-CO combination chemotherapy: the EMA-CO regimen includes etoposide injection, methotrexate for injection, dactinomycin for injection, ifosfamide for injection, and vincristine sulfate for injection. These medications work through different mechanisms to jointly inhibit the growth and division of tumor cells.
It is recommended to rest adequately during chemotherapy, avoid excessive fatigue, maintain a light and easily digestible diet, and avoid spicy foods and beverages. Additionally, regular monitoring of blood routine tests and liver and kidney function indicators can help detect and manage chemotherapy-related side effects promptly.
